Mayne Pharma Group's market cap is currently ―. The company's EPS TTM is AU$-2.928; its P/E ratio is -2.32; Mayne Pharma Group is scheduled to report earnings on August 23, 2024, and the estimated EPS forecast is AU$-0.16. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 22	Jun 21	Jun 20	Jun 19	Jun 18
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	-	-	-	-	-
EBITDA	-	-	-	-	-
Net Income Common Stockholders	-	-	-	-	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	AU$ 96.67M	AU$ 97.98M	AU$ 137.78M	AU$ 89.00M	AU$ 94.06M
Total Assets	AU$ 1.29B	AU$ 1.46B	AU$ 1.83B	AU$ 1.64B	AU$ 1.83B
Total Debt	AU$ 413.67M	AU$ 346.82M	AU$ 398.05M	AU$ 369.38M	AU$ 374.19M
Net Debt	AU$ 316.99M	AU$ 248.84M	AU$ 260.26M	AU$ 280.38M	AU$ 280.13M
Total Liabilities	AU$ 730.81M	AU$ 691.61M	AU$ 782.87M	AU$ 622.26M	AU$ 595.35M
Stockholders Equity	AU$ 564.77M	AU$ 768.36M	AU$ 1.04B	AU$ 1.01B	AU$ 1.23B
Cash Flow	-
Free Cash Flow	-	-	-	-	-
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-

Currency in AUD

Mayne Pharma Group Earnings and Revenue History

Income Statement >

Mayne Pharma Group Debt to Assets

Balance Sheet >

Mayne Pharma Group Cash Flow

Cash Flow >

Mayne Pharma Group Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing